GlassScriptPhysician profile
Daniel G Sterns
NPI 1083744643
$3,665.23
in general payments reported to CMS, 2019-2025
35 companies · $57.35 in 2025
The $57.35 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $418 · 2021: $598 · 2022: $991 · 2023: $853 · 2024: $18.17 · 2025: $57.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $620.90 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $337.69 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $270.66 | 2020-2023 | Ozempic, Rybelsus |
| Amgen INC. | $258.37 | 2019-2023 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $215.69 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $213.02 | 2021-2023 | |
| Abbvie INC. | $197.97 | 2019-2023 | Vraylar |
| Merck Sharp & Dohme LLC | $184.66 | 2019-2023 | Vaxneuvance, Gardasil 9, Verquvo |
| Astellas Pharma US INC | $128.45 | 2019-2021 | |
| Pfizer INC. | $121.43 | 2019-2024 | |
| Glaxosmithkline, LLC. | $118.15 | 2019-2023 | Shingrix, Arexvy |
| Exact Sciences Corporation | $104.43 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $98.51 | 2022 | |
| Allergan, INC. | $90.18 | 2020 | |
| Amarin Pharma, INC. | $74.98 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $66.43 | 2019 | |
| Eisai INC. | $60.80 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $60.35 | 2022-2023 | Jynarque |
| Almatica Pharma LLC | $49.33 | 2022-2023 | Loreev Xr |
| Sanofi Pasteur INC. | $46.21 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.00 | 2021 | |
| Lilly USA, LLC | $41.13 | 2022-2023 | Jardiance |
| Boston Scientific Corporation | $36.49 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.22 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $26.65 | 2023 | Crysvita |
| Kyowa Kirin, INC. | $25.47 | 2023 | |
| Genentech USA, INC. | $22.46 | 2021 | |
| Bausch Health US, LLC | $18.18 | 2019 | |
| Shield Therapeutics INC | $17.42 | 2022 | |
| Qiagen, LLC | $17.36 | 2021 | |
| Ibsa Pharma INC. | $15.49 | 2022 | |
| Edwards Lifesciences Corporation | $15.47 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bardy Diagnostics, INC. | $15.01 | 2020 | |
| Sunovion Pharmaceuticals INC. | $13.46 | 2022 | |
| Daiichi Sankyo INC. | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sterns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.